Cargando…
NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics
Nuclear protein in testis (NUT) carcinoma is a rare, highly aggressive, poorly differentiated carcinoma occurring mostly in adolescents and young adults. This tumor usually arises from the midline structures of the thorax, head, and neck, and exhibits variable degrees of squamous differentiation. NU...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966081/ https://www.ncbi.nlm.nih.gov/pubmed/35372003 http://dx.doi.org/10.3389/fonc.2022.860830 |
_version_ | 1784678577941250048 |
---|---|
author | Moreno, Vanessa Saluja, Karan Pina-Oviedo, Sergio |
author_facet | Moreno, Vanessa Saluja, Karan Pina-Oviedo, Sergio |
author_sort | Moreno, Vanessa |
collection | PubMed |
description | Nuclear protein in testis (NUT) carcinoma is a rare, highly aggressive, poorly differentiated carcinoma occurring mostly in adolescents and young adults. This tumor usually arises from the midline structures of the thorax, head, and neck, and exhibits variable degrees of squamous differentiation. NUT carcinoma is defined by the presence of a NUTM1 (15q14) rearrangement with multiple other genes. In about 70-80% of the cases, NUTM1 is involved in a balanced translocation with the BRD4 gene (19p13.12), leading to a BRD4-NUTM1 fusion oncogene. Other variant rearrangements include BRD3-NUTM1 fusion (~15-20%) and NSD3-NUTM1 fusion (~6%), among others. The diagnosis of NUT carcinoma requires the detection of nuclear expression of the NUT protein by immunohistochemistry. Additional methods for diagnosis include the detection of a NUTM1 rearrangement by fluorescence in situ hybridization or by reverse transcriptase PCR. NUT carcinoma is usually underrecognized due to its rarity and lack of characteristic histological features. Therefore, the goal of this review is to provide relevant recent information regarding the clinicopathologic features of NUT carcinoma, the role of the multiple NUTM1 gene rearrangements in carcinogenesis, and the impact of understanding these underlying molecular mechanisms that may result in the development of possible novel targeted therapies. |
format | Online Article Text |
id | pubmed-8966081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89660812022-03-31 NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics Moreno, Vanessa Saluja, Karan Pina-Oviedo, Sergio Front Oncol Oncology Nuclear protein in testis (NUT) carcinoma is a rare, highly aggressive, poorly differentiated carcinoma occurring mostly in adolescents and young adults. This tumor usually arises from the midline structures of the thorax, head, and neck, and exhibits variable degrees of squamous differentiation. NUT carcinoma is defined by the presence of a NUTM1 (15q14) rearrangement with multiple other genes. In about 70-80% of the cases, NUTM1 is involved in a balanced translocation with the BRD4 gene (19p13.12), leading to a BRD4-NUTM1 fusion oncogene. Other variant rearrangements include BRD3-NUTM1 fusion (~15-20%) and NSD3-NUTM1 fusion (~6%), among others. The diagnosis of NUT carcinoma requires the detection of nuclear expression of the NUT protein by immunohistochemistry. Additional methods for diagnosis include the detection of a NUTM1 rearrangement by fluorescence in situ hybridization or by reverse transcriptase PCR. NUT carcinoma is usually underrecognized due to its rarity and lack of characteristic histological features. Therefore, the goal of this review is to provide relevant recent information regarding the clinicopathologic features of NUT carcinoma, the role of the multiple NUTM1 gene rearrangements in carcinogenesis, and the impact of understanding these underlying molecular mechanisms that may result in the development of possible novel targeted therapies. Frontiers Media S.A. 2022-03-16 /pmc/articles/PMC8966081/ /pubmed/35372003 http://dx.doi.org/10.3389/fonc.2022.860830 Text en Copyright © 2022 Moreno, Saluja and Pina-Oviedo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Moreno, Vanessa Saluja, Karan Pina-Oviedo, Sergio NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics |
title | NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics |
title_full | NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics |
title_fullStr | NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics |
title_full_unstemmed | NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics |
title_short | NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics |
title_sort | nut carcinoma: clinicopathologic features, molecular genetics and epigenetics |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966081/ https://www.ncbi.nlm.nih.gov/pubmed/35372003 http://dx.doi.org/10.3389/fonc.2022.860830 |
work_keys_str_mv | AT morenovanessa nutcarcinomaclinicopathologicfeaturesmoleculargeneticsandepigenetics AT salujakaran nutcarcinomaclinicopathologicfeaturesmoleculargeneticsandepigenetics AT pinaoviedosergio nutcarcinomaclinicopathologicfeaturesmoleculargeneticsandepigenetics |